Merck's Keytruda nets another approval, this time in triple negative breast cancer. Can it catch up to Tecentriq?

Another day, another win for Merck’s blockbuster Keytruda.

The FDA has granted accelerated approval for the cash cow combined with chemotherapy in triple negative breast cancer, giving the drug the green light in its 18th different cancer. Monday’s new indication comes for patients with PD-L1-expressing tumors with a Combined Positive Score of at least 10.